» Articles » PMID: 38317802

Co-occurrence of Bacteria and Viruses and Serotype Distribution of in the Nasopharynx of Tanzanian Children Below 2 years of Age Following Introduction of the PCV13

Overview
Specialty Public Health
Date 2024 Feb 6
PMID 38317802
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Pneumococcal conjugate vaccines have reduced severe disease attributed to vaccine-type pneumococci in children. However, the effect is dependent on serotype distribution in the population and disease development may be influenced by co-occurrence of viral and bacterial pathogens in the nasopharynx.

Methods: Following introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Tanzania we performed repeated cross-sectional surveys, including 775 children below 2 years of age attending primary healthcare centers. All children were sampled from nasopharynx and pneumococci were detected by single-target PCR. Pneumococcal serotypes/groups and presence of viruses and other bacteria were determined by two multiplex PCR assays.

Results: The prevalence of PCV13 vaccine-type pneumococci decreased by 50%, but residual vaccine-types were still detected in 21% of the children 2 years after PCV13 introduction. An increase in the non-vaccine-type 15 BC was observed. Pneumococci were often co-occurring with , and detection of rhino/enterovirus was associated with higher pneumococcal load.

Discussion: We conclude that presence of residual vaccine-type and emerging non-vaccine-type pneumococci in Tanzanian children demand continued pneumococcal surveillance. High co-occurrence of viral and bacterial pathogens may contribute to the disease burden and indicate the need of multiple public health interventions to improve child health in Tanzania.

Citing Articles

Analysis of Adverse Events Post-13-Valent Pneumococcal Vaccination among Children in Hangzhou, China.

Wang J, Du J, Liu Y, Che X, Xu Y, Han J Vaccines (Basel). 2024; 12(6).

PMID: 38932305 PMC: 11209216. DOI: 10.3390/vaccines12060576.

References
1.
Elfving K, Shakely D, Andersson M, Baltzell K, Ali A, Bachelard M . Acute Uncomplicated Febrile Illness in Children Aged 2-59 months in Zanzibar - Aetiologies, Antibiotic Treatment and Outcome. PLoS One. 2016; 11(1):e0146054. PMC: 4731140. DOI: 10.1371/journal.pone.0146054. View

2.
Swarthout T, Ibarz-Pavon A, Kawalazira G, Sinjani G, Chirombo J, Gori A . A pragmatic health centre-based evaluation comparing the effectiveness of a PCV13 schedule change from 3+0 to 2+1 in a high pneumococcal carriage and disease burden setting in Malawi: a study protocol. BMJ Open. 2021; 11(6):e050312. PMC: 8212416. DOI: 10.1136/bmjopen-2021-050312. View

3.
Lo S, Gladstone R, van Tonder A, Lees J, du Plessis M, Benisty R . Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis. 2019; 19(7):759-769. PMC: 7641901. DOI: 10.1016/S1473-3099(19)30297-X. View

4.
Skosana Z, von Gottberg A, Olorunju S, Mohale T, du Plessis M, Adams T . Non-vaccine serotype pneumococcal carriage in healthy infants in South Africa following introduction of the 13-valent pneumococcal conjugate vaccine. S Afr Med J. 2021; 111(2):143-148. DOI: 10.7196/SAMJ.2021.v111i2.14626. View

5.
Satzke C, Turner P, Virolainen-Julkunen A, Adrian P, Antonio M, Hare K . Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine. 2013; 32(1):165-79. DOI: 10.1016/j.vaccine.2013.08.062. View